Stefan Laufer
#113,044
Most Influential Person Now
German pharmacist
Stefan Laufer's AcademicInfluence.com Rankings
Download Badge
Chemistry
Why Is Stefan Laufer Influential?
(Suggest an Edit or Addition)According to Wikipedia, Stefan Laufer is a German pharmacist and professor for pharmaceutical chemistry at the Eberhard Karls University of Tübingen. Laufer is author of more than 500 publications, author of 15 book chapters and inventor of more than 43 patent families with over 347 international applications.
Stefan Laufer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Candidate drugs against SARS-CoV-2 and COVID-19 (2020) (437)
- Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. (2019) (280)
- Determination of the wound healing effect of Calendula extracts using the scratch assay with 3T3 fibroblasts. (2009) (271)
- In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer (2014) (252)
- Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord (2016) (208)
- A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer (2016) (194)
- The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. (2004) (156)
- Licofelone Suppresses Prostaglandin E2 Formation by Interference with the Inducible Microsomal Prostaglandin E2 Synthase-1 (2008) (156)
- Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI (2008) (155)
- Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. (2001) (155)
- The Cysteinome of Protein Kinases as a Target in Drug Development. (2018) (144)
- Biological studies on Brazilian plants used in wound healing. (2009) (139)
- Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position. (2004) (139)
- PGE2 in the regulation of programmed erythrocyte death (2005) (136)
- Accelerated Clearance of Plasmodium-infected Erythrocytes in Sickle Cell Trait and Annexin-A7 Deficiency (2009) (129)
- New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. (2006) (119)
- Progress towards a public chemogenomic set for protein kinases and a call for contributions (2017) (118)
- (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. (1994) (109)
- Studies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica flowers. (2002) (108)
- In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis. (2001) (108)
- Small molecular anti‐cytokine agents (2006) (107)
- Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. (2012) (106)
- IL‐1β, IL‐18, and eicosanoids promote neutrophil recruitment to pore‐induced intracellular traps following pyroptosis (2016) (106)
- The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2 (2002) (104)
- COX-3: just another COX or the solitary elusive target of paracetamol? (2003) (103)
- Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. (2015) (99)
- The Gastrointestinal Tolerability of the LOX/COX Inhibitor, Licofelone, is Similar to Placebo and Superior to Naproxen Therapy in Healthy Volunteers: Results From a Randomized, Controlled Trial (2004) (95)
- Proteasome Activation by Small Molecules. (2017) (95)
- Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. (2014) (93)
- Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. (2008) (93)
- Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. (2003) (90)
- Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore? (2000) (88)
- Participation of leukotriene C(4) in the regulation of suicidal erythrocyte death. (2009) (82)
- Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket (2016) (82)
- Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. (2002) (81)
- In vitro cytotoxic activity of abietane diterpenes from Peltodon longipes as well as Salvia miltiorrhiza and Salvia sahendica. (2011) (80)
- Three-component combinatorial synthesis of novel dihydropyrano[2,3-c]pyrazoles. (2008) (78)
- Flavonoids Inhibit COX-1 and COX-2 Enzymes and Cytokine/Chemokine Production in Human Whole Blood (2015) (77)
- Inhibition of GSK3 differentially modulates NF-kappaB, CREB, AP-1 and beta-catenin signaling in hepatocytes, but fails to promote TNF-alpha-induced apoptosis. (2008) (74)
- Inhibitors of c-Jun N-terminal kinases: an update. (2015) (73)
- Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. (2005) (73)
- Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. (2002) (73)
- Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection (2009) (72)
- The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases (2005) (71)
- Role of eicosanoids in structural degradation in osteoarthritis (2003) (70)
- Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids. (2004) (69)
- Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors. (2008) (68)
- Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant. (2016) (67)
- Arachidonoyl-phosphatidylcholine oscillates during the cell cycle and counteracts proliferation by suppressing Akt membrane binding (2013) (67)
- Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review (2016) (67)
- Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region. (2008) (65)
- Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. (2016) (65)
- Small-molecule-induced Rho-inhibition: NSAIDs after spinal cord injury (2012) (64)
- MALDI-TOF MS analysis of urinary nucleosides (2005) (63)
- Targeting the Gatekeeper MET146 of C-Jun N-Terminal Kinase 3 Induces a Bivalent Halogen/Chalcogen Bond. (2015) (62)
- Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site. (2017) (62)
- The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase (2001) (62)
- COX‐3—a virtual pain target in humans? (2003) (62)
- Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). (2009) (62)
- Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC–ITMS coupling (2005) (61)
- Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males (2017) (61)
- 3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta. (2009) (61)
- Triggering of Suicidal Erythrocyte Death by Ruxolitinib (2015) (60)
- Abietane diterpenes induce cytotoxic effects in human pancreatic cancer cell line MIA PaCa-2 through different modes of action. (2012) (60)
- Tri- and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases. (2012) (59)
- Ones, thiones, and N-oxides: an exercise in imidazole chemistry. (2002) (59)
- Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients (2008) (58)
- Donated chemical probes for open science (2018) (56)
- Imidazole inhibitors of cytokine release: probing substituents in the 2 position. (2002) (55)
- The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway (2004) (55)
- Antitubercular Isoniazid and Drug Resistance of Mycobacterium tuberculosis — A Review (2002) (54)
- Triggering of Suicidal Erythrocyte Death Following Boswellic Acid Exposure (2015) (54)
- Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions. (2016) (54)
- Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles. (2008) (53)
- Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis. (2005) (52)
- ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. (1994) (51)
- Are vanadium compounds drugable? Structures and effects of antidiabetic vanadium compounds: a critical review. (2005) (50)
- Anti-inflammatory activity of myricetin-3-O-β-D-glucuronide and related compounds (1998) (49)
- Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer. (2008) (49)
- c-Jun N-terminal kinase inhibitors: a patent review (2010 – 2014) (2015) (45)
- Fucoxanthin Induced Suicidal Death of Human Erythrocytes (2015) (45)
- Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping. (2017) (44)
- Discovery and development of ML3000 (2001) (44)
- Catechin derivatives from Parapiptadenia rigida with in vitro wound-healing properties. (2010) (43)
- Identification of urinary modified nucleosides and ribosylated metabolites in humans via combined ESI-FTICR MS and ESI-IT MS analysis (2008) (43)
- Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors. (2002) (42)
- A smartphone readout system for gold nanoparticle-based lateral flow assays: application to monitoring of digoxigenin (2019) (41)
- p38 MAPK inhibitors: a patent review (2012 – 2013) (2014) (41)
- Biological Evaluation and Structural Determinants of p38α Mitogen‐Activated‐Protein Kinase and c‐Jun‐N‐Terminal Kinase 3 Inhibition by Flavonoids (2010) (40)
- Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases. (2015) (40)
- From imidazoles to pyrimidines: new inhibitors of cytokine release. (2002) (39)
- Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis (2003) (39)
- Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors. (2006) (39)
- Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling (2007) (38)
- Novel lead structures for p38 MAP kinase via FieldScreen virtual screening. (2009) (38)
- From five- to six-membered rings: 3,4-diarylquinolinone as lead for novel p38MAP kinase inhibitors. (2007) (38)
- Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX. (2012) (38)
- Successful structure-based design of recent p38 MAP kinase inhibitors. (2009) (38)
- IL-1β Regulates FHL2 and Other Cytoskeleton-Related Genes in Human Chondrocytes (2008) (38)
- Implications for selectivity of 3,4-diarylquinolinones as p38alphaMAP kinase inhibitors. (2008) (37)
- Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast). (2006) (37)
- The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells. (2012) (37)
- Stimulation of Suicidal Erythrocyte Death by Lipoxygenase Inhibitor Bay-Y5884 (2006) (36)
- Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold. (2018) (36)
- Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. (2001) (36)
- Are MAP Kinases Drug Targets? Yes, but Difficult Ones (2007) (36)
- An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays. (2005) (35)
- Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in patients with knee osteoarthritis (2008) (34)
- Optimization of a nonradioactive immunosorbent assay for p38alpha mitogen-activated protein kinase activity. (2010) (34)
- An updated patent review of p38 MAP kinase inhibitors (2014-2019) (2020) (34)
- Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3. (2017) (34)
- Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors. (2010) (33)
- Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors. (2012) (33)
- Identification of rosmarinic acid as the major active constituent in Cordia americana. (2010) (32)
- Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy (2021) (32)
- Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity. (2008) (32)
- Sesquiterpene lactones as inhibitors of IL-8 expression in HeLa cells. (2006) (32)
- Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. (1994) (32)
- An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs. (2002) (32)
- Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle. (2010) (31)
- Osteoarthritis therapy--are there still unmet needs? (2004) (31)
- Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and 1H NMR. (2003) (31)
- Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity. (2013) (30)
- Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4- chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid. (1995) (30)
- Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase. (2012) (30)
- Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1 H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor. (2006) (30)
- Rapid and easy access to indoles via microwave-assisted Hemetsberger-Knittel synthesis (2009) (29)
- Stimulating Effect of Sclareol on Suicidal Death of Human Erythrocytes (2016) (29)
- Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes (2014) (29)
- Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow. (2005) (29)
- Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. (2008) (28)
- Role of the hydrogen bonding heteroatom-Lys53 interaction between the p38alpha mitogen-activated protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors. (2009) (28)
- Fine-tuned PEGylation of chitosan to maintain optimal siRNA-nanoplex bioactivity. (2016) (28)
- Assessing the target differentiation potential of imidazole-based protein kinase inhibitors. (2012) (27)
- Impact of p38 MAP Kinase Inhibitors on LPS-Induced Release of TNF-α in Whole Blood and Primary Cells from Different Species (2015) (27)
- In vitro metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS (2007) (27)
- The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands (2007) (26)
- Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation (2013) (26)
- Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib (2013) (26)
- A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives (2019) (26)
- Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting. (2017) (26)
- Novel Hinge‐Binding Motifs for Janus Kinase 3 Inhibitors: A Comprehensive Structure–Activity Relationship Study on Tofacitinib Bioisosteres (2014) (25)
- Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors. (2010) (25)
- A Multicomponent Carba‐Betti Strategy to Alkylidene Heterodimers – Total Synthesis and Structure–Activity Relationships of Arzanol (2012) (25)
- The effects of ML 3000 on antigen-induced responses in sheep. (1997) (25)
- General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3- dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals. (1995) (25)
- A fraction of stem bark extract of Entada africana suppresses lipopolysaccharide-induced inflammation in RAW 264.7 cells. (2013) (25)
- Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with COX/5-LOX inhibitory activity (2002) (24)
- Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical properties. (2009) (24)
- Natural chromones as potential anti-inflammatory agents: Pharmacological properties and related mechanisms. (2019) (24)
- Substituted Isoxazoles as Potent Inhibitors of p38 MAP Kinase (2006) (24)
- Isoxazolone based inhibitors of p38 MAP kinases. (2008) (24)
- A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors. (2012) (24)
- New frontiers in kinases: second generation inhibitors. (2014) (23)
- Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity. (2006) (23)
- 2‐Acylaminopyridin‐4‐ylimidazoles as p38 MAP Kinase Inhibitors: Design, Synthesis, and Biological and Metabolic Evaluations (2009) (23)
- p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011) (2011) (23)
- Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors (1999) (23)
- Antinociceptive, anti-inflammatory and gastroprotective effects of a hydroalcoholic extract from the leaves of Eugenia punicifolia (Kunth) DC. in rodents. (2014) (23)
- Synthesis and Evaluation of a Novel Series of Pyrrolizine Derivatives as Dual Cyclooxygenase‐1 and 5‐Lipoxygenase Inhibitors (1997) (23)
- Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors. (2020) (22)
- Dynamics in the p38alpha MAP kinase-SB203580 complex observed by liquid-state NMR spectroscopy. (2008) (22)
- A concise and optimized four-step approach toward 2-(aryl-)alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles using alkyl- or arylalkyl thiocyanates (2006) (22)
- Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors. (2007) (22)
- Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors. (2010) (22)
- Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3 (2018) (22)
- Entada africana fraction CH2Cl2/MEOH 5% inhibits inducible nitric oxide synthase and pro-inflammatory cytokines gene expression induced by lipopolysaccharide in microglia (2013) (21)
- Targeting Cancer Stem Cells with Defined Compounds and Drugs (2013) (21)
- Metabolically stable dibenzo[b,e]oxepin-11(6H)-ones as highly selective p38 MAP kinase inhibitors: optimizing anti-cytokine activity in human whole blood. (2013) (20)
- Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine. (2017) (20)
- Gastrointestinal tolerance of [2,2-dimethyl-6-(4-chlorophenyl-7-phenyl- 2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in the rat. (1994) (20)
- A direct ELISA assay for quantitative determination of the inhibitory potency of small molecules inhibitors for JNK3. (2011) (20)
- Pharmacophore design of p38α MAP kinase inhibitors with either 2,4,5-trisubstituted or 1,2,4,5-tetrasubstituted imidazole scaffold. (2011) (20)
- Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor alpha or interleukin 1 beta release in vitro and ex vivo. (2003) (20)
- Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase. (2010) (20)
- Pharmacokinetics of ML3403 ({4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-Type p38 Mitogen-Activated Protein Kinase Inhibitor (2007) (20)
- Design, Synthesis and Structure–Activity Relationship of Functionalized Tetrahydro‐β‐carboline Derivatives as Novel PDE5 Inhibitors (2011) (19)
- Selective p38α MAP kinase/MAPK14 inhibition in enzymatically modified LDL‐stimulated human monocytes: implications for atherosclerosis (2017) (19)
- Click Chemistry: Novel Applications in Cell Biology and Drug Discovery. (2017) (19)
- Discovery of Novel Orally Active Anti-Inflammatory N-Phenylpyrazolyl-N-Glycinyl-Hydrazone Derivatives That Inhibit TNF-α Production (2012) (19)
- Development of first lead structures for phosphoinositide 3-kinase-C2γ inhibitors. (2015) (19)
- Regulation of coronary venular barrier function by blood borne inflammatory mediators and pharmacological tools: insights from novel microvascular wall models. (2012) (19)
- Colocalization of the VEGF‐R2 and the common IL‐3/GM‐CSF receptor beta chain to lipid rafts leads to enhanced p38 activation (2009) (19)
- Antimicrobial and antileukemic effects: in vitro activity of Calyptranthes grandifolia aqueous leaf extract (2020) (18)
- Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1 (2020) (18)
- Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. (2012) (18)
- Chiral sulfoxides as metabolites of 2-thioimidazole-based p38α mitogen-activated protein kinase inhibitors: enantioselective synthesis and biological evaluation. (2011) (18)
- Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors. (2019) (18)
- One-pot synthesis of 4,6-diaryl-2-oxo(imino)-1,2-dihydropyridine-3-carbonitrile; a New Scaffold for p38alpha MAP kinase inhibition. (2010) (18)
- A New In Vitro Model to Study Cellular Responses after Thermomechanical Damage in Monolayer Cultures (2013) (18)
- In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and -2 and 5-Lipoxygenase (2008) (17)
- Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases. (2017) (17)
- SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions (2021) (17)
- Quantitative determination of piritramide in human plasma and urine by off- and on-line solid-phase extraction liquid chromatography coupled to tandem mass spectrometry. (2006) (17)
- Achiral-chiral LC/LC-MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism. (2005) (17)
- Combining aptamers and antibodies: Lateral flow quantification for thrombin and interleukin-6 with smartphone readout (2021) (17)
- Differential effects of p38MAP kinase inhibitors on the expression of inflammation‐associated genes in primary, interleukin‐1β‐stimulated human chondrocytes (2010) (17)
- Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors. (2010) (16)
- Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine. (2017) (16)
- Human whole blood assay for rapid and routine testing of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclo-oxygenase-2 activity (2008) (16)
- Determination of (R)- and (S)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry. (2004) (16)
- Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors. (2009) (15)
- High anti-inflammatory activity of harpagoside-enriched extracts obtained from solvent-modified super- and subcritical carbon dioxide extractions of the roots of Harpagophytum procumbens. (2006) (15)
- Deoxyhypusine Hydroxylase from Plasmodium vivax, the Neglected Human Malaria Parasite: Molecular Cloning, Expression and Specific Inhibition by the 5-LOX Inhibitor Zileuton (2013) (15)
- Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination (2022) (15)
- c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer’s Diseases (2020) (15)
- NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation. (2017) (15)
- Mass spectrometric pathway monitoring of secondary metabolites: systematic analysis of culture extracts of Streptomyces species. (2004) (14)
- Synthesis and biological identification of the acyl glucuronide of the antiinflammatory drug ML-3000 (1997) (14)
- In Vivo Hypoxia PET Imaging Quantifies the Severity of Arthritic Joint Inflammation in Line with Overexpression of Hypoxia-Inducible Factor and Enhanced Reactive Oxygen Species Generation (2017) (14)
- Duplex Shiny app quantification of the sepsis biomarkers C-reactive protein and interleukin-6 in a fast quantum dot labeled lateral flow assay (2020) (14)
- Interference of Boswellic Acids with the Ligand Binding Domain of the Glucocorticoid Receptor (2014) (14)
- Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase. (2009) (14)
- New insights into novel inhibitors against deoxyhypusine hydroxylase from plasmodium falciparum: compounds with an iron chelating potential (2015) (14)
- A fast iterative synthetic approach towards the identification of novel highly selective p38 MAP kinase inhibitors. (2019) (14)
- Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes (2005) (14)
- SCISSOR—Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol (2016) (14)
- NO‐Donors (VII [1]): Synthesis and Cyclooxygenase Inhibitory Properties of N‐and S‐Nitrooxypivaloyl‐cysteine Derivatives of Naproxen — A Novel Type of NO‐NSAID (2002) (13)
- From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors. (2016) (13)
- Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition. (2015) (13)
- Regiospecific and Highly Flexible Synthesis of 1,4,5-Trisubstituted 2-Sulfanylimidazoles from Structurally Diverse Ethanone Precursors (2008) (13)
- Regioisomeric 3-, 4- and 5-aminomethyl isoxazoles: synthesis and muscarinic activity (1995) (13)
- Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. (2021) (12)
- Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactions (2019) (12)
- Anti-inflammatory activity of myricetin-3-O-beta-D-glucuronide and related compounds. (1998) (12)
- Extract from gum resin of Boswellia serrata decreases IA(2)-antibody in a patient with "Late onset Autoimmune Diabetes of the Adult" (LADA). (2014) (12)
- Neuromodulatory effects of Calyptranthes grandifolia extracts against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. (2016) (12)
- Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration. (2021) (12)
- Structural and conformational analysis of proanthocyanidins from Parapiptadenia rigida and their wound-healing properties. (2011) (12)
- A Highly Selective In Vitro JNK3 Inhibitor, FMU200, Restores Mitochondrial Membrane Potential and Reduces Oxidative Stress and Apoptosis in SH-SY5Y Cells (2021) (12)
- A p38 Substrate-Specific MK2-EGFP Translocation Assay for Identification and Validation of New p38 Inhibitors in Living Cells: A Comprising Alternative for Acquisition of Cellular p38 Inhibition Data (2014) (11)
- Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK (2020) (11)
- Drug discovery: a modern decathlon. (2013) (11)
- LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer (2021) (11)
- Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitors. (2010) (11)
- Myricetin inhibits panel of kinases implicated in tumorigenesis (2019) (11)
- The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen‐Activated Protein Kinase Inhibitors (2015) (11)
- Synthesis, p38 kinase inhibitory and anti-inflammatory activity of new substituted benzimidazole derivatives. (2012) (11)
- Development of a p38δ mitogen activated protein kinase ELISA assay for the quantitative determination of inhibitor activity. (2012) (10)
- Identification of new γ-hydroxybutenolides that preferentially inhibit the activity of mPGES-1. (2012) (10)
- A direct enzyme-linked immunosorbent assay (ELISA) for the quantitative evaluation of Janus Kinase 3 (JAK3) inhibitors (2014) (10)
- Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA-induced arthritis in rats. (2014) (10)
- Review of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19 (2020) (10)
- Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors. (2013) (10)
- Biosynthesis of iron oxide magnetic nanoparticles using clinically isolated Pseudomonas aeruginosa (2021) (10)
- Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen Synthase Kinase-3β Inhibitors (2019) (9)
- Pyridinylimidazoles as GSK3β Inhibitors: The Impact of Tautomerism on Compound Activity via Water Networks. (2019) (9)
- In vitro activities of Ceiba speciosa (A.St.-Hil) Ravenna aqueous stem bark extract (2019) (9)
- Synthesis and Biological Testing of N‐Aminoimidazole‐Based p38α MAP Kinase Inhibitors (2010) (9)
- Influence of p38MAPK inhibition on IL-1beta-stimulated human chondrocytes: a microarray approach. (2009) (9)
- Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors (2022) (9)
- Mapping the S1 and S1’ subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents (2019) (9)
- linked immunosorbent assay ( ELISA ) for the quantitative evaluation of Janus Kinase 3 ( JAK 3 ) inhibitors (2014) (9)
- Neuropsychiatric Disorders and COVID-19: What We Know So Far (2021) (9)
- Bioisosteric Replacement of Arylamide-linked Spine Residues by N-Acylhydrazones and Selenophenes as Design Strategy to Novel Dibenzosuberone Derivatives as Type I½ p38 MAP Kinase Inhibitors. (2020) (8)
- Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation. (2019) (8)
- Selective targeting of the αC and DFG-out pocket in p38 MAPK. (2020) (8)
- Effect of TGFβ on calcium signaling in megakaryocytes. (2015) (8)
- HPLC determination of etofenamate and flufenamic acid in biological material. (1988) (8)
- Influence of annexin A7 on insulin sensitivity of cellular glucose uptake (2015) (8)
- Inferential NMR/X-ray-based structure determination of a dibenzo[a,d]cycloheptenone inhibitor-p38α MAP kinase complex in solution. (2012) (8)
- Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1). (2016) (8)
- Modeling and Benchmark Data Set for the Inhibition of c-Jun N-terminal Kinase-3 (2011) (7)
- Current jakinibs for the treatment of rheumatoid arthritis: a systematic review (2021) (7)
- Neuroprotective Effect of Luteolin-7-O-Glucoside against 6-OHDA-Induced Damage in Undifferentiated and RA-Differentiated SH-SY5Y Cells (2022) (7)
- From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4). (2020) (7)
- Hypertensive effects and structure-activity relationships of 5-omega-aminoalkyl isoxazoles. (1993) (7)
- Four New Flavonol Glycosides from the Leaves of Brugmansia suaveolens (2014) (7)
- Identification of urinary nucleosides by ESItTOFmMS (2006) (7)
- A Special View of What Was Almost Forgotten: p38δ MAPK (2021) (7)
- Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors. (2021) (7)
- Hypertensiv wirksame 5‐(β‐Aminoethyl)aminoisoxazole: Synthese und Prüfung von Isoxazolopyrazinen und Isoxazolodiazepinen (1991) (7)
- The application of Stille cross-coupling reactions with multiple nitrogen containing heterocycles (2011) (7)
- Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor. (2021) (7)
- The European Federation for Medicinal Chemistry (EFMC) Best Practice Initiative: Validating Chemical Probes (2020) (7)
- Conformational effects on potency of thioimidazoles and dihydrothiazolines (2011) (7)
- Are peptides a solution for the treatment of hyperactivated JAK3 pathways? (2019) (7)
- Chemical Probes for Understudied Kinases: Challenges and Opportunities. (2021) (7)
- Design, Synthesis and Biological Evaluation of Novel Pyrazolo[1,2,4]triazolopyrimidine Derivatives as Potential Anticancer Agents (2021) (6)
- ACKR3 regulates platelet activation and ischemia-reperfusion tissue injury (2022) (6)
- Regiospecific and Highly Flexible Synthesis of 1,4,5-Trisubstituted 2-Sulfanylimidazoles from Structurally Diverse Ethanone Precursors. (2008) (6)
- Bioequivalence evaluation of two flutamide preparations in healthy female subjects. (1997) (6)
- Publication Criteria and Requirements for Studies on Protein Kinase Inhibitors─What Is Expected? (2022) (6)
- Distribution and excretion of [14C]-labelled [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5- yl]- [2'-14C]-acetic acid in rats. (1995) (6)
- P38 Kinase, SGK1 and NF-κB Dependent Up-Regulation of Na+/Ca2+ Exchanger Expression and Activity Following TGFß1 Treatment of Megakaryocytes (2017) (6)
- Metabolic signature of breast cancer cell line MCF–7: Profiling of modified nucleosides via LC-IT MS coupling (2008) (6)
- Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites. (2021) (6)
- Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis (2019) (6)
- Synthesis and structure‐activity‐relationship of 3,4‐Diaryl‐1H‐pyrrolo[2,3‐b]pyridines as irreversible Inhibitors of mutant EGFR‐L858R/T790M (2019) (6)
- Neuroprotective potential of Myrciaria plinioides D. Legrand extract in an in vitro human neuroblastoma model (2019) (6)
- Studies on the in vitro and in vivo genotoxicity of [2,2-dimethyl-6- (4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid. (1995) (6)
- {nBuMg(OR)}2 und {Mg(OR)2}2 (R = 2, 4, 6‐tBu3C6H2) – sterisch überfrachtete Magnesiumalkoholate (2012) (5)
- From 2-Alkylsulfanylimidazoles to 2-Alkylimidazoles: An Approach towards Metabolically More Stable p38α MAP Kinase Inhibitors (2017) (5)
- 5-(2-Aminoethyl)-3-aryl-5-phenylaminoisoxazole durch Ringtransformation von 2-Phenacylidenimidazolidinen (1989) (5)
- Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung (2018) (5)
- Lungenkrebs: EGFR‐Inhibitoren mit hoher Wirksamkeit gegen die therapieresistente L858R/T790M/C797S‐Mutante. (2016) (5)
- 4-(4-Fluorophenyl)-1-(4-nitrophenyl)-3-(pyridin-4-yl)-1H-pyrazol-5-amine (2012) (5)
- Modeling of Compound Profiling Experiments Using Support Vector Machines (2014) (5)
- The effect of single‐dose naproxen on eicosanoid formation in human gastroduodenal mucosa (2006) (5)
- tert-Butyl N-(4-methyl-2-pyridyl)carbamate (2008) (5)
- Effect of TGFβ on Na+/K+ ATPase activity in megakaryocytes. (2014) (5)
- Cytokines and Growth Factors in the Treatment of Osteoarthritis: What Could be the Best Disease Modifying Drugs (2005) (5)
- Visual aptamer-based capillary assay for ethanolamine using magnetic particles and strand displacement (2019) (5)
- Kinase inhibitor data set for systematic analysis of representative kinases across the human kinome (2020) (4)
- An optimized and versatile synthesis to pyridinylimidazole-type p38α mitogen activated protein kinase inhibitors. (2015) (4)
- Discovery and Evaluation of Enantiopure 9H-pyrimido[4,5-b]indoles as Nanomolar GSK-3β Inhibitors with Improved Metabolic Stability (2020) (4)
- A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors. (2010) (4)
- Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4. (2020) (4)
- The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery (2021) (4)
- Three‐Component Combinatorial Synthesis of Novel Dihydropyrano[2,3‐c]pyrazoles. (2008) (4)
- The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer (2021) (4)
- New Horizons in Drug Discovery - Understanding and Advancing Kinase Inhibitors. (2020) (4)
- Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer. (2022) (4)
- Effiziente Synthese neuer 2‐Cycloalk(en)yl‐propansäure‐Derivate – mittlere und große Ringe als Bioisostere von Alkylphenylresten? (1996) (4)
- 4-(4-Fluorophenyl)-1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine (2012) (4)
- Neue Anwendungen der Klick‐Chemie in Zellbiologie und Wirkstoffentwicklung (2017) (4)
- Enaminodiester und ‐monoester mit semicyclischer CC‐Bindung der Pyrrolidin‐ und Imidazolidin‐Reihe (1988) (4)
- Synthesis, Characterization, and in vivo Distribution of Intracellular Delivered Macrolide Short‐Chain Fatty Acid Derivatives (2021) (4)
- Regioisomeric 3-, 4-, and 5-Aminomethylisoxazoles: Synthesis and Muscarinic Activity. (1996) (3)
- Alkoxymagnesium Iodide Complexes (2011) (3)
- Eine neue Synthese für 3,4-Diaryl-5-oxo-4,5-dihydroisoxazole und ihre Überführung in 5-[N-(ω-Aminoalkyl)amino)isoxazole und 5-(2-Aminoethylthio)isoxazole (1989) (3)
- Efficient Synthesis of New 2‐Cycloalk(en)ylpropanoic Acid Derivatives—Medium and Large Rings as Bioisosteres of Alkylphenyl Moieties? (1996) (3)
- A Concise and Optimized Four‐Step Approach Toward 2‐(Aryl‐)alkylsulfanyl‐, 4(5)‐Aryl‐, 5(4)‐Heteroaryl‐Substituted Imidazoles Using Alkyl‐ or Arylalkyl Thiocyanates. (2007) (3)
- 2-(4-Fluorophenyl)-3-(4-pyridyl)pyrido[2,3-b]pyrazine (2009) (3)
- (3RS,1SR)-3-Bromo-3-(1-phenylpropyl)chroman-2,4-dione (2005) (3)
- A Diverse and Versatile Regiospecific Synthesis of Tetrasubstituted Alkylsulfanylimidazoles as p38α Mitogen-Activated Protein Kinase Inhibitors (2018) (3)
- Hypertensiv wirksame 5‐(β‐Aminoethyl)aminoisoxazole: Synthese und Prüfung von Derivaten mit teilrigidisierter C‐5‐Seitenkette bzw. ω‐ständigem Heterocyclus (1990) (3)
- Synthesis and Cyclooxygenase Inhibitory Properties of Novel (+) 2‐(6‐Methoxy‐2‐naphthyl)propanoic Acid (Naproxene) Derivatives (2001) (3)
- New Horizons in Drug Discovery - Understanding and Advancing Different Types of Kinase Inhibitors Seven Years in Kinase Inhibitor Research with Impressive Achievements and New Future Prospects. (2021) (3)
- Development of a Microsphere-Based p38α Kinase No-Wash Assay (2006) (3)
- 2-(4-Fluorophenyl)-N-{4-[6-(4-fluorophenyl)-2,3-dihydroimidazo[2,1-b][1,3]thiazol-5-yl]pyridin-2-yl}acetamide (2010) (3)
- Development and optimization of a non-radioactive JNK3 assay. (2006) (3)
- 4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl]pyridin-2(1H)-one (2007) (3)
- Advancing the kinase field: new targets and second generation inhibitors. (2015) (3)
- Zur Reaktion von Triphenylphosphan mit Thionylchlorid (2012) (3)
- Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2) (2021) (3)
- Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors. (2021) (2)
- 4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazol-5-amine (2012) (2)
- 3-(4-Bromophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (2012) (2)
- One, Thione undN-Oxide: ein allgemeiner Zugang zu Imidazolderivaten (2002) (2)
- Facile synthesis of model indazolo〔2,1-c〕〔1,3,4〕benzotriazepine-5,13-diones (2008) (2)
- Special Issue: Kinase inhibitors (2018) (2)
- Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships. (2020) (2)
- SARS-CoV-2 Mutations in Brazil: From Genomics to Clinical Conditions (2021) (2)
- Synthesis, X-ray diffraction study and pharmacological evaluation of 3-amino-4-methylthiophene-2-acylcarbohydrazones. (2018) (2)
- Chemical Space Exploration of Oxetanes (2020) (2)
- 4-[5-Amino-4-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-1-yl]benzonitrile (2012) (2)
- Ethyl 5-amino-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1H-pyrazole-4-carboxylate dimethyl sulfoxide hemisolvate (2012) (2)
- 3-(2-Fluorophenyl)-6-(phenoxymethyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole (2008) (2)
- Methacryloyl-GlcNAc Derivatives Copolymerized with Dimethacrylamide as a Novel Antibacterial and Biocompatible Coating (2021) (2)
- Target Hopping from Protein Kinases to PXR: Identification of Small-Molecule Protein Kinase Inhibitors as Selective Modulators of Pregnane X Receptor from TüKIC Library (2022) (2)
- Inside Cover: Synthesis and Biological Testing of N-Aminoimidazole-Based p38α MAP Kinase Inhibitors (ChemMedChem 7/2010) (2010) (2)
- N-{4-[3-(4-Fluorophenyl)pyrido[2,3-b]pyrazin-2-yl]-2-pyridyl}isopropylamine (2009) (2)
- The scratch assay: A suitable in vitro tool for studying wound healing effects (2008) (2)
- Dapsone is not a Pharmacodynamic Lead Compound for its Aryl Derivatives. (2020) (2)
- Arzneistoffentwicklung, ein moderner Zehnkampf (2013) (2)
- Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors. (2019) (2)
- An aptamer based thermofluorimetric assay for ethanolamine. (2019) (2)
- Effects of natural products containing acylresorcinol partial structures on cyclooxygenases and 5-lipoxygenase. (2001) (2)
- Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor (2020) (1)
- Substituted Benzamides from Anti-inflammatory and p38 Kinase Inhibitors to Antitubercular Activity: Design, Synthesis and Screening. (2018) (1)
- N-[(3RS,4RS)-1-Benzyl-4-methylpiperidin-3-yl]-5-nitro-1-phenylsulfonyl-1H-pyrrolo[2,3-b]pyridine-4-amine (2012) (1)
- 4-(4-Fluorophenyl)-3-(4-pyridyl)quinolin-2(1H)-one (2006) (1)
- P139 EFFECT OF LYSOSOMAL SHORT CHAIN FATTY ACID DELIVERY ON IMMUNE RESPONSE (2020) (1)
- 1-[(3RS,4RS)-1-Benzyl-4-methylpiperidin-3-yl]-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine hemihydrate (2012) (1)
- International Conference on Inflammopharmacology – VIII Side-Effects of Anti-Inflammatory Drugs Symposium (2003) (1)
- N-[(3RS,4SR)-1-Benzyl-4-methylpiperidin-3-yl]-1-(4-methylphenylsulfonyl)-5-nitro-1H-pyrrolo[2,3-b]pyridin-4-amine (2012) (1)
- CHAPTER 6:Anti-Inflammatory Macrolides to Manage Chronic Neutrophilic Inflammation (2014) (1)
- [Medical chemistry and molecular mechanisms of tyrosine kinase inhibitors. The viewpoint of pharmaceutical research]. (2008) (1)
- Adjunctive role of Calyptranthes tricona extract with probiotic Kluyveromyces marxianus on colorectal adenocarcinoma Caco-2 cells (2019) (1)
- Inside Back Cover: The Cysteinome of Protein Kinases as a Target in Drug Development (Angew. Chem. Int. Ed. 16/2018) (2018) (1)
- N-{(Z)-2-[1-(Triisopropylsilyl)-1H-indol-3-yl]-2-(triisopropylsilyloxy)vinyl}-2-(3,4,5-trimethoxyphenyl)acetamide (2007) (1)
- M1739 Ml3403, a New p38 MAPK Inhibitor, Corrects Immune Dysfunction in Rodent Models of Chronic Inflammatory Disorders (2010) (1)
- 4-[4-(4-Fluorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-3-yl]-1-methylpyridinium iodide–4-[3-(4-fluorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-4-yl]-1-methylpyridinium iodide (0.6/0.4) (2007) (1)
- A Convenient Synthesis of 1-(4-Fluorophenyl)-2-(4-pyridyl)cyclopentene from Cyclopentanone (2008) (1)
- Discovery of a Novel Series of Tetrahydro‐β‐carbolines Inducing Autophagic Cell Death in Human Metastatic Melanoma (2014) (1)
- 3-(4-Fluorophenyl)-6-methoxy-2-(4-pyridyl)quinoxaline (2009) (1)
- Anti-inflammatory Activities of Phenoxyphenyl Ureas Mediated by Inhibition of p38 Kinase (2015) (1)
- Multi-gram Preparation of 7-Nitroquinoxalin-2-amine (2017) (1)
- 3,4-Bis(4-fluorophenyl)-1,2,5-oxadiazole 2-oxide (2006) (1)
- Are Two Better Than One in Rheumatoid Arthritis? Development of Dual p38α MAPK/PDE-4 Inhibitors for Treatment of TNFα-Driven Diseases (2017) (1)
- Design and synthesis of novel quinazoline derivatives and their evaluation as PI3Ks inhibitors. (2014) (1)
- tert-Butyl N-benzyl-N-(4-methyl-2-pyridyl)carbamate (2008) (1)
- Spasmolytic effects of STW 5 and its components on ileal contractions induced by acetylcholine, prostaglandin F2α and substance P (2008) (1)
- 4-(4-Fluorophenyl)-2-methyl-3-(1-oxy-4-pyridyl)isoxazol-5(2H)-one (2008) (1)
- Metabolism of a novel skepinone L-like p38 mitogen-activated protein kinase inhibitor (2014) (1)
- Methyl 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-ylsulfanyl]butanoate (2008) (1)
- 3-(2,4-Difluoroanilino)-9-nitrodibenzo[b,e]oxepin-11(6H)-one (2011) (1)
- 4-[5-(4-Fluorophenyl)-1H-imidazol-4-yl]pyridine (2009) (1)
- Hypertensiv wirksame 5‐(ω‐Aminoalkyl)aminoisoxazole: Synthese und Prüfung von Verbindungen mit einer Sulfamid‐ oder Carboxyl‐Gruppe am Ende der Seitenkette (1990) (1)
- Proteinkinase-Inhibitoren: selektiv und wirksam (2015) (1)
- Vioxx® und die anderen Coxibe (2004) (1)
- 4-[3-(4-Fluorophenyl)quinoxalin-2-yl]-N-isopropylpyridin-2-amine (2009) (1)
- 3-(4-Fluorophenyl)-2-(4-pyridyl)pyrido[2,3-b]pyrazine (2009) (1)
- Medizinische Chemie und molekulare Hemmmechanismen der Tyrosinkinase‐Inhibitoren. Schwerpunkt pharmazeutischer Forschung (2008) (1)
- N-{4-[4-(4-Fluorophenyl)-1-(2-methoxyethyl)-2-methylsulfanyl-1H-imidazol-5-yl]-2-pyridyl}-2-methyl-3-phenylpropionamide (2009) (1)
- Discrepancy in interactions and conformational dynamics of pregnane X receptor (PXR) bound to an agonist and a novel competitive antagonist (2022) (1)
- Back Cover: Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes (ChemMedChem 2/2014) (2014) (1)
- Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells. (2022) (1)
- Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors. (2022) (1)
- Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation. (2022) (1)
- Therapeutic Potential of Small Molecules Modulating the Cyclooxygenase–5‐Lipoxygenase Pathway (2012) (1)
- Antiulcerogenic Potential of the Ethanolic Extract of Ceiba speciosa (A. St.-Hil.) Ravenna Evaluated by In Vitro and In Vivo Studies (2022) (1)
- Abstract 257: Evaluation of organic cation transporter 1 (OCT1, SLC22A1) as transporter for sorafenib (2016) (1)
- N-{4-[4-(4-Fluorophenyl)-1-methyl-2-[(R)-methylsulfinyl]-1H-imidazol-5-yl]-2-pyridyl}acetamide dihydrate (2009) (1)
- 4-Chloro-1-(4-methylphenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (2009) (1)
- CHAPTER 5:Dual Inhibition of Phosphodiesterase-4 and p38 MAP Kinase: A Strategy for Treatment of Chronic Inflammatory Diseases (2012) (1)
- Cytotoxic abietane diterpenes from Peltodon longipes and their mode of action (2010) (1)
- High-Throughput Screening Platform in Postnatal Heart Cells and Chemical Probe Toolbox to Assess Cardiomyocyte Proliferation. (2021) (1)
- Data for homogeneous thermofluorimetric assays for ethanolamine using aptamers and a PCR instrument (2019) (1)
- Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe. (2021) (1)
- Four new kaempferol glycosides from the leaves of Brugmansia suaveolens (2011) (1)
- (2Z)-2-Fluoro-N-{4-[5-(4-fluorophenyl)-2-methylsulfanyl-1H-imidazol-4-yl]-2-pyridyl}-3-phenylacrylamide (2009) (1)
- Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivity. (2022) (1)
- The functional role of p38 MAPK pathway in malignant brain tumors (2022) (1)
- Innenrücktitelbild: Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung (Angew. Chem. 16/2018) (2018) (0)
- systemic hypoxia are mediated by PAF and LTB Mesenteric microvascular inflammatory responses to (2015) (0)
- Flavonoids Inhibit COX-1 and COX-2 Enzymes and Cytokine/Chemokine Production in Human Whole Blood (2014) (0)
- 3-(4-Fluorophenyl)-4-(4-pyridyl)quinolin-2(1H)-one (2006) (0)
- 3‐(4‐Fluorophenyl)‐1‐methyl‐4‐(4‐pyridyl)quinolin‐2(1H)‐one (2007) (0)
- Poly[[tetramethanolbis[4-oxo-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-olato]disodium]–diethyl ether–methanol (1/1/2)] (2016) (0)
- N-{2-Methyl-5-[(5-oxo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-2-yl)amino]phenyl}benzamide (2010) (0)
- Enamino Diesters and Monoesters with a Semicyclic C=C Bond of the Pyrrolidine and Imidazolidine Series. (1988) (0)
- [Hypertensive action of 5-(beta-aminoethyl)aminoisoxazoles: synthesis and screening of isoxazolopyrazines and isoxazolodiazepines]. (1991) (0)
- tert-Butyl N-benzyl-N-[4-(4-fluorobenzoylmethyl)-2-pyridyl]carbamate (2008) (0)
- Effects of Substance P and Neurotensin on the contractility of ileum of mice in vitro: Inhibition by plant extract STW 5 (Iberogast®) (2007) (0)
- 4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl]pyridine (2006) (0)
- rac‐(3E,3aR,6aR)‐3‐(Hydroxymethylene)‐3,3a,6,6a‐tetrahydro‐2H‐cyclopenta[b]furan‐2‐one (2007) (0)
- 6-Amino-1-benzyl-4-(4-chlorophenyl)-3-(4-pyridyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (2008) (0)
- Chinolinylmethoxyaryl-Verbindungen als duale Inhibitoren der Cyclooxygenase und 5-Lipoxygenase (1998) (0)
- Design and Synthesis of Novel Quinazoline Derivatives and Their Evaluation as PI 3 Ks Inhibitors (2014) (0)
- A New Synthesis of 3,4-Diaryl-5-oxo-4,5-dihydroisoxazoles and Their Transformation to 5-(N-(ω-Aminoalkyl)amino)isoxazoles and 5-(2-Aminoethylthio)isoxazoles. (1989) (0)
- tert-Butyl N-[(3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl]-N-methylcarbamate (2013) (0)
- Retraction Statement: Paper by Qian Y, Ma J, Guo X, Sun J, Yu Y, CaoB, Zhang L, Ding X, Huang J, Shao JF, entitled ‘Curcumin Enhances the Radiosensitivity ofU87 Cells by Inducing DUSP-2 Up-Regulation‘ Cell Physiol Biochem 2015;35(4):1381-93.doi: 10.1159/000373959 (2016) (0)
- Catechin derivatives from Parapiptadenia rigida: biological studies and conformational analysis (2010) (0)
- 5‐(β‐Aminoethyl)aminoisoxazoles with Hypertensive Activity: Synthesis and Screening of Isoxazolopyrazines and Isoxazolodiazepines. (1991) (0)
- Dibenzocycloheptanverbindungen und pharmazeutische mittel, welche diese verbindungen enthalten (2006) (0)
- Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie (1994) (0)
- 4-[2-(4-Fluorophenyl)furan-3-yl]pyridine (2009) (0)
- Multiplex in vivo RNAi screening instructs combination therapies to increase the therapeutic efficacy of the multikinase inhibitor sorafenib (2013) (0)
- Metabolische Signatur der Mammakarzinomzell-Linie MCF-7: Profiling modifizierter Nukleoside mittels LC-IT MS (2008) (0)
- N-[3-(5-Oxo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-2-ylamino)phenyl]furan-3-carboxamide (2010) (0)
- Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie (1994) (0)
- Pharmazeutische Wissenschaften zum Wohle der Patienten (2016) (0)
- Makrolidkonjugate von pyrrolizin- und indolizinverbindungen als inhibitoren von 5-lipooxygenase und cyclooxygenase (2006) (0)
- Posters: Osteoarthritis (2014) (0)
- 2‐(4‐Fluorophenyl)‐1‐(4‐pyridyl)cyclopentan‐1‐ol (2007) (0)
- MKK4 Inhibitors—Recent Development Status and Therapeutic Potential (2023) (0)
- Ethyl (2,3-dihydro-1H,1′H-2,3′-biindol-1-yl)glyoxylate (2007) (0)
- United States Patent (2007) (0)
- N-(4-Chloropyridin-2-yl)-N-methoxymethyl-4-methylbenzenesulfonamide (2010) (0)
- 4-Chloro-7-methoxymethyl-2-phenyl-7H-pyrrolo[2,3-b]pyridine (2010) (0)
- COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease (2023) (0)
- Author response: Donated chemical probes for open science (2018) (0)
- The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation (2023) (0)
- Improved Multigram Route to a Tricyclic Key Intermediate for Dibenzosuberone-Based p38 Inhibitors via an Optimized Early-Stage Heck Coupling (2021) (0)
- Efficient Synthesis of New 2-Cycloalk(en)ylpropanoic Acid Derivatives - Medium and Large Rings as Biosteres of Alkylphenyl Moieties? (1996) (0)
- (2aRS,3RS,4aSR,6aRS,6bSR)-3-Hydroxy-2a,3,4a,6,6a,6b-hexahydro-1,4-dioxacyclopenta[cd]pentalen-2(5H)-one (2007) (0)
- Effects of STW 5 and its single extracts on ileal oxygen radical production induced by histamine (2009) (0)
- Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19 (2023) (0)
- Ring Transformation of 2-Phenacylidenimidazolidines into 5-(2-Aminoethyl)-3-aryl-5-phenylaminoisoxazoles. (1989) (0)
- 2,2‐Dimethyl‐N‐[3‐(3,4,5‐trimethoxybenzoyl)pyridin‐4‐yl]propanamide (2007) (0)
- (1aR,2aS,5aS,5bS)-Perhydro-4H-oxireno[3,4]cyclopenta[1,2-b]furan-4-one (2007) (0)
- Super-conserved receptors expressed in the brain: biology and medicinal chemistry efforts. (2022) (0)
- 4-[3-(4-Fluorophenyl)-5-isopropylisoxazol-4-yl]pyridine (2006) (0)
- Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448). (2022) (0)
- Correction to Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases. (2015) (0)
- Rapid and Easy Access to Indoles via Microwave‐Assisted Hemetsberger—Knittel Synthesis. (2009) (0)
- Transient exposure of macrophages to P38 map kinase inhibition conditions cell responses through MAPK activated protein kinase-2 regulation (2011) (0)
- Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands (2022) (0)
- Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors (2022) (0)
- Pharmacokinetics of ML3403 ( -(1-phenylethyl)-amine), a 4-Pyridinylimidazole-Type p38 Mitogen-Activated Protein Kinase Inhibitor (2007) (0)
- ' s response to reviews Title : Prediction of breast cancer by profiling of urinary RNA metabolites using SVM-based feature selection (2009) (0)
- 3-(2,4-Dimethoxyanilino)-8-methoxydibenz[b,e]oxepin-11(6H)-one (2011) (0)
- Abstract 1257: A MYC-Aurka protein complex represents an actionable target in p53 altered liver cancer (2016) (0)
- New Cyclic amides, processes for their preparation and their use (2007) (0)
- P59 Diarylpyrrolizines; dual inhibitors of CO and 5-LO (1994) (0)
- 4-(4-Fluorophenyl)-1-methoxymethyl-2-phenyl-1H-imidazole (2009) (0)
- Synthesis of an EGFR Inhibitor (2016) (0)
- Small Molecular anti-Cytokine Agents (2006) (0)
- New Frontiers in Kinases: Second Generation Inhibitors-Going beyond Cancer. (2015) (0)
- 1,4-Dimethyl-2-phenyl-6,7-dihydro-1H-pyrazolo[4,3-b]pyridine-3,5(2H,4H)-dione (2011) (0)
- Efficacious Anti-inflammatory and Respiratory Drugs: Development from 1965 to 2014 (2015) (0)
- Influence of annexin A7 on insulin sensitivity of cellular glucose uptake (2014) (0)
- A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives (2019) (0)
- Direct 3D printed biocompatible microfluidics: assessment of human mesenchymal stem cell differentiation and cytotoxic drug screening in a dynamic culture system (2022) (0)
- [What's in the future? New NSAIDs]. (2002) (0)
- 2-thio-subsituierte imidazolderivative and their use in pharmacy (2002) (0)
- Cell receptor-ligand interaction, signalling, activation and apoptosis 21. Pregnenolone Sulphate is Similar to Dexamethasone in Supressing the Unfettered Secretion of Hyaluronan: In Vitro Study on Cultured Synovial Fibroblasts from Patients with Longstanding Rheumatoid Arthritis (2011) (0)
- 2‐(6‐Methoxy‐7H‐purin‐7‐yl)‐1‐phenylethanone monohydrate (2007) (0)
- Optimierte Bindungsdauer am Zielenzym: Typ-I1/2 -Inhibitoren der p38α-MAP-Kinase mit verbesserter Bindungskinetik durch direkte Interaktion mit der R-Spine (2017) (0)
- Choline salt and tromethamine licofelone (2009) (0)
- New pyrrole derivatives, their preparation process and pharmaceutical compositions containing them. (1995) (0)
- Ready-to-use nanopore platform for ethanolamine quantification using an aptamer-based strand displacement assay (2023) (0)
- Design, Synthesis and SAR of Phenylamino-Substituted 5,11-Dihydrodibenzo[a,d]cyclohepten-10-ones and 11H-Dibenzo[b,f]oxepin-10-ones as p38 MAP Kinase Inhibitors. (2010) (0)
- Abstract 4377: Liver X receptor mediated lipotoxicity represents a treatment option for liver cancer (2019) (0)
- Regioisomeric 5(3)‐Aminomethyl‐3(5)‐phenylisoxazoles: Synthesis, Spectroscopic Discrimination, and Muscarinic Activity. (1995) (0)
- New insights into novel inhibitors against deoxyhypusine hydroxylase from plasmodium falciparum: compounds with an iron chelating potential (2015) (0)
- Rosmarinic acid as the effective compound in Cordia americana (2010) (0)
- The MAP kinase JNK3 as target for halogen bonding (2015) (0)
- Neural regeneration research model to be explored: SH-SY5Y human neuroblastoma cells (2022) (0)
- N1-{4-[2-(Methylthio)-1H-imidazol-5-yl]pyridin-2-yl}benzene-1,4-diamine (2019) (0)
- 6-(4-Chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-carbaldehyde (2011) (0)
- CCDC 958070: Experimental Crystal Structure Determination (2017) (0)
- Crystal structure of JAK3 in complex with FM601 (compound 10a) (2020) (0)
- The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma (2019) (0)
- Novel Approach to Pharmaceutical 3D-Printing Omitting the Need for Filament—Investigation of Materials, Process, and Product Characteristics (2022) (0)
- 7-[4-(4-Fluorophenyl)-2-methylsulfanyl-1H-imidazol-5-yl]tetrazolo[1,5-a]pyridine (2010) (0)
- N-(6-Chloro-3-nitropyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)isoquinolin-3-amine (2021) (0)
- Are peptides a solution for the treatment of hyperactivated JAK3 pathways? (2019) (0)
- 5-((β-Aminoethyl)amino)isoxazoles with Hypertensive Activity: Synthesis and Screening of Derivatives with Partially Rigid C-5 Side Chains and Heterocycles at the ω-Position Respectively. (2010) (0)
- Immune cell targeted fumaric esters support a role of GPR109A as a primary target of monomethyl fumarate in vivo. (2023) (0)
- 2-(3-{(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}oxetan-3-yl)acetonitrile monohydrate (2014) (0)
- Synthesis and Evaluation of a Novel Series of Pyrrolizine Derivatives (VII) as Dual Cyclooxygenase‐1 and 5‐Lipoxygenase Inhibitors. (1998) (0)
- 11th German Conference on Chemoinformatics (GCC 2015) (2016) (0)
- 1-[2-(Benzylamino)-4-pyridyl]-2-(4-fluorophenyl)ethane-1,2-dione (2009) (0)
- 2-[5-Bromo-1-(3-chlorobenzyl)-2-methyl-1H-indol-3-yl]acetic acid (2012) (0)
- 2-(Bicyclo[2.2.1]hept-5-en-2-yl)-1H-pyrrolo[2,3-b]pyridine (2010) (0)
- Development of a microsphere-based p38alpha MAP kinase no-wash assay. (2006) (0)
- Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis (2019) (0)
- Ring Transformations of 2-Phenacylidenimidazolidines: Synthesis of 5-(β-Aminoethyl)anilinopyrazoles and 2-Acyl-3-(β-aminoethyl)aminothiophenes. (1990) (0)
- Derivatives useful in the treatment of allergic diseases or rheumatic heterocyclic, their preparation process and pharmaceutical compositions containing them. (1995) (0)
- Inhibition of histamine-induced inflammatory reactions in intestinal mucosa by STW 5 (2010) (0)
- Novel avenue towards liver regeneration and treatment of acute and chronic liver diseases: safety and PK profile from a first-in human (FIH) clinical trial for HRX-0215 as first in class MKK4 inhibitor (2022) (0)
- 2-(3,4,5-Trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridine (2009) (0)
- Isostearic acid is an active component of imiquimod formulations used to induce psoriaform disease models (2023) (0)
- Dataset (VII) related to publication: Decisive Role of Water and Protein Dynamics in Residence Time of p38a MAP Kinase Inhibitors (2021) (0)
- Controlling the Covalent Reactivity of a Kinase Inhibitor with Light (2021) (0)
- Synergy of R-(–)carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation (2022) (0)
- Pyrrolitsiini- and pyrrolo [2,1-b] thiazole derivatives and their use in pharmacy (1996) (0)
- Anti-inflammatory and antileukemia potential of myrciaria Sp. ethanol extract (2017) (0)
- 2‐(6‐Amino‐7H‐purin‐7‐yl)‐1‐phenylethanone (2007) (0)
- Simplifying Submission Requirements for the Journal of Medicinal Chemistry. (2021) (0)
- Synthesis and Cyclooxygenase Inhibitory Properties of Novel (+) 2-(6-Methoxy-2-naphthyl)propanoic Acid (Naproxene) Derivatives. (2010) (0)
- 2-arylalkylthio-imidazole, 2-Arylalkenylthio-imidazoles and 2-Arylalkinylthio-imidazoles as inflammation inhibitors and inhibitors of cytokine release (1998) (0)
- Abstract B167: KRAS gene mutations are associated with tumor resistance toward the LN1222/AD736 p38 inhibitor (2018) (0)
- Facile Synthesis of Model Indazolo[2,1‐c][1,3,4]benzotriazepine‐5,13‐diones. (2009) (0)
- Transient exposure of macrophages to p38 MAPK inhibition conditions cell responses through MAPK activated protein kinase-2 (MK-2) regulation (2011) (0)
- In vitro and in vivo anti-inflammatory and anticoagulant activities of Myrciaria plinioides D. Legrand ethanol leaf extract (2021) (0)
- 1-[4-(2-Aminoanilino)phenyl]-2,2,2-trifluoroethanone (2010) (0)
- Antiinflammatory oxo and hydroxy derivatives of pyrrolizines and use thereof in the pharmaceutical field (1999) (0)
- Design, Synthesis and Structure—Activity Relationship of Functionalized Tetrahydro-β-carboline Derivatives as Novel PDE5 Inhibitors. (2011) (0)
- N-(4-Chloropyridin-2-yl)-N-(4-methylphenylsulfonyl)acetamide (2010) (0)
- [Hypertensive action of 5-(omega-aminoalkyl)aminoisoxazole: synthesis and testing of compounds with a sulfamide or carboxyl group on the end of side chain]. (1990) (0)
- (4R)-4-Hydroxy-1-[(2S)-2-hydroxydodecyl]-l-proline monohydrate (2006) (0)
- [Hypertensive acting 5-(beta-aminoethyl)aminoisoxazoles: synthesis and screening of derivatives with with partially rigid C-5 side chains and omega-position heterocyclics]. (1990) (0)
- 2-[(1-Methyl-1H-pyrrol-2-yl)carbonylmethyl]isoindoline-1,3-dione (2009) (0)
- Fused pyrrole compounds, pharmaceutical compositions containing them and their use (2000) (0)
- (A) -annelloidut pyrrole derivatives and their use in pharmacy (1996) (0)
- Human p38 MAP Kinase in Complex with 2-amino-phenylamino- dibenzosuberone (2011) (0)
- 4-[2-(4-Fluorophenyl)-1H-pyrrol-3-yl]pyridine (2009) (0)
- 6-(4-Methoxyphenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-carbaldehyde (2011) (0)
- Targeting Proteinkinases: The Selectivity Problem (2009) (0)
- Compounds fused pyrrole rings, pharmaceutical compositions containing them and use thereof. (2001) (0)
- [Pharmazie in unserer Zeit 5/2008]. (2008) (0)
- 5-(4-Fluorophenyl)-4-(4-pyridyl)-1,3-oxazol-2-amine (2010) (0)
- Neue NSAR: Was bietet die Zukunft? (2002) (0)
- 2,2,2‐Trifluoroethanol‐mediated hydroarylation of fluorinated alkynes with indoles: Application to diindolylmethanes (2022) (0)
- NO-Donors. Part 7. Synthesis and Cyclooxygenase Inhibitory Properties of N- and S-Nitrooxypivaloyl-cysteine Derivatives of Naproxen — A Novel Type of NO-NSAID. (2003) (0)
This paper list is powered by the following services:
Other Resources About Stefan Laufer
What Schools Are Affiliated With Stefan Laufer?
Stefan Laufer is affiliated with the following schools:
